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Abstract: Background: We investigated the impact of fish oil and/or probiotics on serum and vaginal
inflammatory and metabolic proteins and their relation to the onset of gestational diabetes mellitus
(GDM). Methods: Overweight/obese pregnant women received fish oil + placebo, probiotics +
placebo, fish oil + probiotics or placebo + placebo from early pregnancy until six months postpartum
(fish oil: 1.9 g docosahexaenoic acid and 0.22 g eicosapentaenoic acid; probiotics: Lactobacillus rhamno-
sus HN001 and Bifidobacterium animalis ssp. lactis 420, 1010 colony-forming units each). Serum high
sensitivity C-reactive protein (hsCRP) and serum/vaginal (s/v) phosphorylated insulin-like growth
factor binding-protein-1 (phIGFBP-1), IGFBP-1 and matrix metalloproteinase 8 (MMP-8) were ana-
lyzed. GDM was diagnosed according to 2 h 75 g OGTT. Results: The intervention had no impact on
the change in proteins during pregnancy. Nevertheless, s-MMP-8 decreased and s-IGFBP-1 increased
more in obese than in overweight women in the fish oil + probiotics group, while a decrease in
s-MMP-8 was seen in obese women and an increase was seen in overweight women in the probiotics
+ placebo group. The late pregnancy s-phIGFBP-1 was higher in women who developed GDM in
fish oil + probiotics-group compared to fish oil + placebo-group. The concentrations of s-phIGFBP-1
(635.9 ± 315.3 ng/mL vs. 753.2 ± 335.1 ng/mL, p = 0.005) and s-IGFBP-1 (3.78 ± 0.72 ng/mL vs.
3.96 ± 0.69 ng/mL, p = 0.042) were lower in early pregnancy in women who developed GDM than
in women remaining healthy. Conclusions: The intervention per se had no impact on the proteins,
but obesity and GDM may modify the effect. IGFBPs may affect the development of GDM.
Keywords: low-grade inflammation; IGFBP-1; MMP-8; obesity; pregnancy
1. Introduction
Both increased low-grade inflammation and higher adiposity have been linked to ges-
tational diabetes mellitus (GDM) [1], which is a serious condition in pregnancy, increasing
the risk of metabolic complications in both mother and child. Mechanistically, higher adi-
posity increases the concentration of circulating pro-inflammatory markers which may
lead to insulin resistance, simultaneously decreasing the levels of insulin-like growth factor
binding-protein 1 (IGFBP-1) and increasing the bioavailability of IGF-1 [2]. Pregnancy itself
causes changes in the metabolism, specifically in insulin and glucose metabolism, but
may result in excessive disturbances and thus GDM. IGFBP-1, and especially the phos-
phorylated (ph) form of IGFBP-1, and matrix metalloproteinase 8 (MMP-8) measured
either from vaginal or cervical fluid have been used as markers for preterm birth [3,4] and
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intra-amniotic inflammation [5,6], respectively. Moreover, there is preliminary evidence
that lower serum concentrations IGFBP-1 and higher serum concentrations of MMP-8 may
be linked to low-grade inflammation [7,8] and obesity [9,10], providing initial evidence of
use as metabolic markers as well.
The risk of GDM could be potentially modulated by reducing low-grade inflamma-
tion and restoring insulin metabolism via the IGF and MMP systems. Based on previous
studies, n-3 long-chain polyunsaturated fatty acids (LC-PUFA) and probiotics have dis-
played promise in regulating the levels of low-grade inflammatory markers, such as
high-sensitivity C-reactive protein (hsCRP), and metabolic markers, IGFBPs and MMPs.
The level of hsCRP has been shown to decline after interventions with a probiotic [11,12]
or a n-3 LC-PUFA [13–16] in pregnant and non-pregnant subjects although not all reports
agree with these findings [12,17,18]. In terms of IGFBP-1 and MMP-8, dietary intervention
studies in pregnant women are lacking. However, in non-pregnant adult subjects, the
consumption of n-3 LC-PUFA has been shown to increase the serum concentration of
IGF-1 and IGFBP-3 [19–21], whereas probiotic administration has been demonstrated to
increase hepatic IGFBP-2 [22] and white adipose tissue IGFBP-3 [23] concentrations in
experimental animals. With respect to MMP, probiotic consumption has been shown to
increase MMP-9 levels in saliva [24] and decrease those of MMP-8 in gingival crevicular
fluid [25]. Therefore, we hypothesized that it may be possible to interfere with obesity-
related excessive inflammation and disturbed metabolism by administering n-3 LC-PUFA
(fish oil) and/or probiotics to overweight and obese pregnant women, a risk group for
developing pregnancy-related complications.
The objectives are firstly to investigate the impact of fish oil and/or probiotic supple-
mentation from early pregnancy onwards on the serum hsCRP concentration and serum
and vaginal levels of IGFBP-1, phIGFBP-1, and MMP-8 and secondly to determine whether
these low-grade inflammatory and metabolic markers could predict the diagnosis of GDM.
As there are not many studies on phIGFBP-1, IGFBP-1 and MMP-8 during pregnancy, in
this longitudinal study, we have also determined the changes in serum and vaginal levels
of phIGFBP-1, IGFBP-1 and MMP-8 as well as that of hsCRP from early to late pregnancy.
2. Materials and Methods
2.1. Study Design and Subjects
The design of this study has been described in detail previously [26]. In this double-
blind, placebo-controlled randomized trial, the impact of fish oil and/or probiotics on
maternal and child health are studied (ClinicalTrials.gov, NCT01922791). The trial was
conducted in the Turku University Hospital and University of Turku in Finland. The
recruitment started in October 2013 and was completed in July 2017. This study complied
with the Declaration of Helsinki as revised in 2000. The Ethics Committee of the Hospital
District of South-West Finland (115/180/2012) approved the study protocol. Informed
consent form was provided by all participants. A total of 439 overweight and obese women
that are hence at an increased risk for GDM were recruited to the clinical trial and were
randomized into four intervention groups (fish oil + placebo, probiotics + placebo, fish oil +
probiotics and placebo + placebo). One woman who was later discovered to have familiar
hypercholesterolemia was excluded. The study flow is presented in Figure 1 and the study
timeline in Figure 2.
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lemon flav were the same as in fish oil capsul s. Prob otic capsules contained Lactobacil u
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ssp. lactis 420 (DSM 22089; DuPont), each with 1010 colony-forming units per capsule. The
placebo for the probiotics consisted of microcrystalline cellulose and the size, shape and
color were same as the probiotic capsules. The intervention supplements for the on-going
trial (ClinicalTrials.gov, NCT01922791), which aims to investigate both mother and child
health outcomes, were selected based on the previous scientific knowledge. The probiotic L.
rhamnosus HN001 is a well characterized probiotic [27] and B. lactis 420 is a novel probiotic
with demonstrated health benefits related to metabolism in an animal study [28] and
inflammation in humans [29,30]. LC-PUFA, in this case fish oil, which is rich in DHA and
EPA, are known inflammation-resolving dietary factors [31] and are important for fetal and
child development [32], and may possibly reduce insulin resistance [33].
Here, we studied secondary outcomes of the trial, the low-grade inflammation and
IGFBP-1 and MMP-8 as determined from serum and vagina. The participants in whom
a serum or vaginal sample was available at early or late pregnancy, resulting in 434
pregnant women, were included in the analyses. The clinical characteristics of the study
population included in this report were essentially the same as described in detail in
Pellonperä et al. [26]. Women attended two study visits during gestation at early (mean
13.8 ± 2.1 gestational weeks) and late (mean of 35.2 ± 1.0 gestational weeks) pregnancy.
Height was measured by a wall stadiometer in 0.1 cm accuracy. Pre-pregnancy body
mass index (BMI) (kg/m2) was calculated by dividing self-reported weight in kilograms,
obtained from welfare women clinic records, by height measured in the early pregnancy.
Overweight was defined as BMI ≥25 kg/m2, while obesity as BMI ≥30 kg/m2. GDM was
diagnosed with a 2 h 75 g oral glucose tolerance test (OGTT) if one or more values were at or
above the threshold levels: 0 h ≥5.3, 1 h ≥10.0, 2 h ≥8.6 mmol/L, according to the Finnish
Current Care guidelines [34], at a mean of 26.4 ± 2.2 weeks of gestation. OGTT was offered
also to high-risk women (BMI ≥ 35 kg/m2, previous GDM, glucosuria, polycystic ovarian
syndrome, or family risk of diabetes) at early pregnancy, 12–16 weeks of gestation, and
the women who were diagnosed with GDM at early pregnancy were excluded from the
analysis at the onset of GDM.
2.2. Sampling and Analyses
After at least 9 h of overnight fasting, a blood sample was drawn from the antecubital
vein of the mothers. The serum was separated and analyzed for hsCRP and the rest of
the samples were kept at −80 ◦C until analyzed for phIGFBP-1, IGFBP-1 and MMP-8
(Medix Biochemica, Espoo, Finland). HsCRP i.e., low-grade inflammation, was analyzed
by using an automated colorimetric immunoassay on the Dade Behring Dimension RXL au-
toanalyzer (Siemens Healthcare, Camberly, Surrey, UK) in a certified laboratory (TYKSLAB,
the Hospital District of Southwest Finland); the lower limit of detection was 0.1 mg/L. The
data are expressed as mg/L.
Vaginal samples were obtained by research coordinator using sterile swabs (Puritan
Sterile Polyester swabs, Puritan Medical Products Company Co. LLC, Guilford, CT, USA)
and were dissolved in PROM/Partus Specimen Extraction (Medix Biochemica, Espoo,
Finland) and MMP-8 buffer (Medix Biochemica, Espoo, Finland) solutions. The solutions
were kept at −20 ◦C until further analysis.
Concentrations of serum and vaginal IGFBP-1 and phIGFBP-1 were measured by
two immunoenzymometric assays using monoclonal antibodies (Medix Biochemica, Es-
poo, Finland). The IGFBP-1 assay employing monoclonal antibody 6305 detects the non-
phosphorylated and the less phosphorylated isoforms of IGFBP-1, whereas the phIGFBP-1
assay with monoclonal antibody 6303 recognizes the highly phosphorylated forms [35].
The detection limit of both assays was 0.3 ng/mL [36]. The data are expressed as ng/mL.
MMP-8 was quantified with a solid-phase immunoenzymometric assay (MMP-8
IEMA, Medix Biochemica, Espoo, Finland) [5,6]. This sandwich assay uses two monoclonal
antibodies against human MMP-8. Microplate wells are coated with one monoclonal
antibody against MMP-8. The other antibody is conjugated to HRP forming the enzyme
conjugate used to detect the presence of MMP-8. Analyses were performed according to the
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manufacturer’s instructions, and the absorbance of the solutions in the wells was measured
at 414 nm using a microplate reader (Multiskan, Thermo Fisher Scientific, Vantaa, Finland).
The detection limit was 0.04 ng/mL [37]. The data are expressed as ng/mL.
2.3. Statistics
The power calculations of this trial were originally calculated to evaluate the effects of
fish oil and/or probiotic intervention on glycemic status and GDM prevention [26]. The
predefined secondary outcomes were serum hsCRP and serum and vaginal phIGFBP-1,
IGFBP-1 and MMP-8 in this secondary analysis of the main trial. Based on previous studies
investigating the effect of fish oil or probiotics on hsCRP during pregnancy [11–16], the
number of pregnant women in our study was estimated to be adequate. The effect of
fish oil or probiotics on phIGFBP-1, IGFBP-1 and MMP-8 during pregnancy has not been
studied previously. Visual inspection of histograms and Kolmogorov–Smirnov tests were
used for checking the normality distributions of the data. Serum and vaginal markers
(hsCRP, IGFBP-1 and MMP-8) which were not normally distributed were natural log-
transformed since we wanted to apply parametric tests, which can be adjusted and are
statistically more powerful compared to non-parametric tests. A one-way analysis of
variance (ANOVA) test was used for analyzing parametric variables, the Kruskal–Wallis
test was used for non-parametric variables, and Pearson chi-square for categorical variables.
The differences in all women from early to late pregnancy were tested with ANOVA
intervention groups as a fixed factor and the differences between study groups from early
to late pregnancy and at late pregnancy were evaluated with one-way ANOVA. Pearson
correlation was used to study the associations between markers. The markers of interest
were compared between women remaining healthy and those who developed GDM with
ANOVA intervention group as a fixed factor. ANOVA analyses were not adjusted with
insulin since we aimed to test whether phIGFBP-1 and IGFBP-1 could be independent
markers of GDM. Receiver operating characteristics (ROC) analyses were conducted to
investigate the predictive value of phIGFBP-1 and IGFBP-1 and the area under the curve
(AUC) was calculated. ANOVA was used to study the interaction between pre-pregnancy
BMI and the intervention as well as between GDM and the intervention (BMI or GDM ×
intervention group interaction) on the change in serum hsCRP, phIGFBP-1, IGFBP-1, MMP-
8 and vaginal MMP-8 as well as the markers measured in late pregnancy. Furthermore, to
test which intervention groups were affected by a confounding factor, the independent-
samples t-test and one-way ANOVA were used. The independent-samples t-test was used
to study the differences in the markers between overweight and obese pregnant women
in the intervention groups. One-way ANOVA Tukey’s post hoc test was used to study
the impact of the intervention on the markers according to the GDM diagnosis. Results
are shown as mean ± SD or (95%CI), median (IQR), percentage (%) or AUC (95%CI).
p < 0.05 is considered statistically significant. SPSS Statistics 24.0 (IBM, Chicago, IL, USA)
for Windows was used for statistical analyses.
3. Results
3.1. Clinical Characteristics
The mean age of the pregnant women was 30.6 ± 4.6 years. The majority of the
tested pregnant women were overweight (60.4%), with the remainder (39.6%) being obese;
somewhat more than half (54.8%) of the women were highly educated with college or
university degrees, and almost half of the women (48.2%) were expecting their first child.
GDM was diagnosed in 23.1% of the women in late pregnancy [26]. The pregnant women
were normotensive (systolic blood pressure, 117.0 ± 10.3 mmHg; diastolic blood pressure,
76.6 ± 8.4 mmHg) and only 22% of women smoked before pregnancy.
3.2. The Impact of the Dietary Intervention on hsCRP, IGFBP-1 and MMP-8
The fish oil and/or probiotics intervention exerted no impact on the concentrations
of serum hsCRP or serum MMP-8, phIGFBP-1 and IGFBP-1 or vaginal MMP-8 (Table 1).
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However, the impact of the intervention on the change in serum IGFBP-1 and MMP-8 was
influenced by pre-pregnancy BMI (p = 0.04 and p = 0.03 for BMI × intervention group
interaction, respectively). This was related to the differences in these markers between
overweight and obese pregnant women in the probiotics + placebo and fish oil + probiotics
group: in the probiotics + placebo group, MMP-8 decreased in obese pregnant women,
whereas there was an increase in the overweight pregnant women (p = 0.02). In the fish oil
+ probiotics group, the concentration of IGFBP-1 increased more in obese as compared to
overweight (p = 0.008) pregnant women, whereas the level of MMP-8 decreased more in
obese compared to overweight (p = 0.03) women during pregnancy (Table 2).
However, the GDM × intervention group interaction was statistically significant
with respect to serum phIGFBP-1 measured in late pregnancy (p = 0.02); this was at-
tributable to the statistically significantly higher concentration in the fish oil + probiotics
group (mean 1248.10 ± SD 391.48 ng/mL) as compared to the fish oil + placebo group
(mean 854.41 ± SD 392.33 ng/mL) in women who developed GDM in late pregnancy
(p = 0.03).
When the groups consuming fish oil (fish oil + placebo and fish oil + probiotics) were
compared to groups not consuming fish oil (probiotics + placebo and placebo + placebo),
serum hsCRP, phIGFBP-1, IGFBP-1 and MMP-8 and vaginal MMP-8 in early, late or during
pregnancy were not different between the groups. The same result was also seen when
the groups consuming probiotics (probiotics + placebo and fish oil + probiotics) and not
(fish oil + placebo and placebo + placebo) were compared (results not shown).
3.3. HsCRP, IGFBP-1 and MMP-8 as Predictors of GDM
Serum levels of phIGFBP-1 and IGFBP-1 were related to the onset of GDM. Women
who developed GDM in later pregnancy had lower concentrations of phIGFBP-1 (p = 0.005)
and IGFBP-1 (p = 0.042) in early pregnancy than those women who remained healthy
(Table 3). The predictive values of the markers for GDM were as follows: an AUC value
for serum phIGFBP-1 of 0.596 (95% CI 0.53 to 0.67); for IGFBP-1, it was 0.572 (95%CI 0.50
to 0.64), as evaluated with ROC analysis. The serum hsCRP or vaginal MMP-8 at early
pregnancy were not related to the onset of GDM (Table 3).
However, when examining the changes in the levels of hsCRP, phIGFBP-1, IGFBP-1 or
MMP-8 during pregnancy according to the diagnosis of GDM, the concentration of hsCRP
was reduced from early to late pregnancy to a greater extent in the women who developed
GDM (natural log-transformed mean change −0.47 (95%CI −0.62 to −0.33) mg/L) than in
the women who remained healthy (natural log-transformed mean change −0.25 (95%CI
−0.33 to −0.17) mg/L, p = 0.01).
Additionally, the concentration of serum phIGFBP-1 analyzed in late pregnancy was
statistically significantly lower in the women with GDM (mean 1103.72 ± SD 435.50 ng/mL)
as compared to women without GDM (mean 1221.34 ± SD 449.60 ng/mL, p = 0.046) in late
pregnancy. The levels of hsCRP, IGFBP-1 or MMP-8 did not differ between women with
GDM and those without in late pregnancy (results not shown).
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Table 1. The concentrations of early and late pregnancy serum high sensitivity C-reactive protein (hsCRP), matrix metalloproteinase 8 (MMP-8), phosphorylated insulin-like growth factor
binding-protein 1 (phIGFBP-1), IGFBP-1 and vaginal MMP-8 in the different intervention groups and in all of the women. Data are expressed as mean ± SD and 95% Confidence Intervals
for mean change (95%CI).
Fish Oil + Placebo Probiotics + Placebo Fish Oil + Probiotics Placebo + Placebo All
Serum Markers Subjects (n) p Value a
hsCRP (mg/L) b
Early pregnancy 1.68 ± 0.76 1.63 ± 0.79 1.58 ± 0.74 1.57 ± 0.80 1.61 ± 0.77 108/109/108/109/434
Late pregnancy 1.39 ± 0.85 1.32 ± 0.80 1.29 ± 0.78 1.26 ± 0.74 1.32 ± 0.79 93/94/90/92/369 0.72
Mean change −0.29 −0.33 −0.32 −0.30 −0.31 c 92/94/90/91/367 0.97
95%CI −0.43–(−0.15) −0.46–(−0.20) −0.45–(−0.18) −0.44–(−0.16) −0.38–(−0.24) c
MMP-8 (ng/mL) b
Early pregnancy 3.04 ± 0.66 2.90 ± 0.64 2.89 ± 0.60 2.87 ± 0.58 2.93 ± 0.62 107/106/106/108/427
Late pregnancy 2.87 ± 0.73 2.79 ± 0.64 2.75 ± 0.71 2.83 ± 0.70 2.81 ± 0.70 89/89/90/87/355 0.68
Mean change −0.15 −0.11 −0.13 −0.06 −0.11 c 87/86/89/86/348 0.89
95%CI −0.30–0.10 −0.28–0.06 −0.27–0.02 −0.22–0.09 −0.19–(−0.03) c
phIGFBP-1 (ng/mL)
Early pregnancy 708.53 ± 343.32 701.59 ± 340.79 702.04 ± 309.79 696.04 ± 355.21 702.04 ± 336.64 107/107/106/108/428
Late pregnancy 1160.02 ± 509.38 1236.36 ± 489.00 1179.84 ± 422.35 1153.10 ± 380.46 1182.34 ± 452.68 89/88/90/87/354 0.61
Mean change 452.97 490.88 466.85 467.59 469.57 c 87/86/89/86/348 0.93
95%CI 377.67–528.26 404.56–577.21 379.56–554.15 404.64–530.54 430.62–508.53 c
IGFBP-1 (ng/mL) b
Early pregnancy 3.85 ± 0.74 3.84 ± 0.78 3.90 ± 0.73 3.90 ± 0.70 3.87 ± 0.74 107/106/105/108/427
Late pregnancy 4.16 ± 0.63 4.26 ± 0.56 4.23 ± 0.56 4.21 ± 0.60 4.21 ± 0.58 89/88/90/86/353 0.72
Mean change 0.28 0.35 0.33 0.34 0.33 c 87/85/89/85/348 0.83
95%CI 0.17–0.39 0.24–0.46 0.21–0.44 0.22–0.46 0.27–0.38 c
Vaginal markers
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Table 1. Cont.
Fish Oil + Placebo Probiotics + Placebo Fish Oil + Probiotics Placebo + Placebo All
MMP-8 (ng/mL) b
Early pregnancy 3.45 ± 1.62 3.22 ± 1.46 3.06 ± 1.95 3.46 ± 1.59 3.29 ± 1.65 28/29/29/28/115
Late pregnancy 3.44 ± 1.34 3.96 ± 1.48 3.33 ± 1.67 3.64 ± 1.21 3.61 ± 1.44 35/35/27/27/124 0.31
Mean change 0.04 0.55 0.26 −0.04 0.21 c 25/24/19/17/85 0.48
95%CI −0.55−0.63 0.16–0.93 −0.41–0.98 −0.88–0.79 −0.09–0.50 c
a Test between the intervention groups: one-way ANOVA. b Natural log-transformed variables. c Adjusted for intervention.
Table 2. The change in the serum levels of matrix metalloproteinase 8 (MMP-8) and insulin-like growth factor binding-protein 1 (IGFBP-1) (mean change (95%CI)) from early to late
pregnancy in overweight and obese pregnant women subdivided according to the four intervention groups.
Overweight Pregnant Women Obese Pregnant Women n p Value a
Serum MMP-8 (ng/mL) b
Fish oil + Placebo −0.17 (−0.38–0.05) −0.12 (−0.35–0.12) 47/40 0.74
Probiotics + Placebo 0.33 (−0.17–0.23) −0.40 (−0.70–(-0.11)) 58/28 0.02
Fish oil + Probiotics −0.005 (−0.17–0.16) −0.33 (−0.62–(-0.04)) 56/33 0.03
Placebo + Placebo −0.12 (−0.32–0.08) 0.02 (−0.24–0.28) 51/35 0.40
Serum IGFBP-1 (ng/mL) b
Fish oil + Placebo 0.32 (0.18–0.47) 0.23 (0.05–0.42) 47/40 0.44
Probiotics + Placebo 0.32 (0.18–0.45) 0.42 (0.23–0.62) 57/28 0.36
Fish oil + Probiotics 0.20 (0.07–0.33) 0.54 (0.33–0.76) 56/33 0.008
Placebo + Placebo 0.35 (0.20–0.51) 0.32 (0.14–0.51) 51/34 0.81
a Test between overweight and obese pregnant women: independent-samples t-test. b Natural log-transformed variables.
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Table 3. The concentrations of serum matrix metalloproteinase 8 (MMP-8), phosphorylated insulin-
like growth factor binding-protein 1 (phIGFBP-1) and IGFBP-1 and vaginal MMP-8 (mean ± SD)
measured in early pregnancy in those women remaining healthy and in those who developed
gestational diabetes mellitus (GDM) later in pregnancy.
Women Remaining Healthy Women WhoDeveloped GDM
Serum Markers n n p Value a,c
hsCRP (mg/L) b 1.59 ± 0.79 276 1.71 ± 0.61 83 0.22
phIGFBP-1 (ng/mL) 753.24 ±335.11 271
635.85 ±
315.29 82 0.005
IGFBP-1 (ng/mL) b 3.96 ± 0.69 269 3.78 ± 0.72 82 0.042
MMP-8 (ng/mL) b 2.92 ± 0.62 270 2.89 ± 0.61 82 0.77
Vaginal markers
MMP-8 (ng/mL) b 3.42 ± 1.53 69 2.97 ± 1.52 29 0.19
a Test between women remaining healthy and women who developed GDM: ANOVA. b Natural
log-transformed variables. c Adjusted for intervention.
3.4. Evolution of Low-Grade Inflammation, IGFBP-1 and MMP-8 over Pregnancy
As presented in Table 2, the low-grade inflammation measured as serum hsCRP
(natural log-transformed mean change −0.31 (95%CI −0.38 to −0.24) ng/mL) decreased
from early to late pregnancy (Figure S1). The concentration of serum MMP-8 (natural log-
transformed mean change −0.11 (95%CI −0.19 to −0.03) ng/mL) decreased whereas serum
phIGFBP-1 (mean change 469.57 (95%CI 430.62 to 508.53) ng/mL) and IGFBP-1 (natural log-
transformed mean change 0.33 (95%CI 0.27 to 0.38) ng/mL) increased from early to late
pregnancy. In contrast, no change in the vaginal MMP-8 level (natural log-transformed
mean change 0.21 (95%CI −0.09 to 0.50) ng/mL) was detected during the pregnancy.
Vaginal phIGFBP-1 was detected in only 27 of the analyzed samples (n = 115) in early
pregnancy and in 42 samples (out of 122 samples) at late pregnancy, while IGFBP-1 was
measurable in only 14 samples in early (out of 115 samples) and in 16 samples (out of
122 samples) in late pregnancy, and therefore further statistical analyses were conducted
only for MMP-8.
The serum markers did not correlate with vaginal MMP-8 either in early or late
pregnancy (data not shown). On the other hand, weak correlations between serum hsCRP
and phIGFBP-1, IGFBP-1 and MMP-8 were detected. The level of hsCRP measured in early
pregnancy correlated inversely with the serum phIGFBP-1 concentration in early and late
pregnancy (r = −0.131, p = 0.007, r = −0.206, p < 0.001, respectively) and positively with
serum IGFBP-1 (r = 0.121, p = 0.02) and inversely with serum MMP-8 (r = −0.189, p < 0.001)
levels in late pregnancy. In late pregnancy, the hsCRP level correlated with the level of
serum MMP-8 (r = 0.137, p = 0.01) and with the change in serum MMP-8 occurring during
pregnancy (r = 0.118, p = 0.03). The change in the hsCRP concentration correlated with the
serum IGFBP-1 level measured in late pregnancy (r = 0.142, p = 0.008).
4. Discussion
We observed that serum phIGFBP-1 and IGFBP-1 were related to the onset of GDM.
The serum levels of both these markers were lower in early pregnancy in women who
later developed GDM as compared to those who remained healthy. Moreover, phIGFBP-1
was also lower in late pregnancy in women with established GDM compared to healthy
women. Instead, the administration of fish oil and/or probiotics from early pregnancy
onwards did not modify per se the change occurring during the pregnancy of serum
low-grade inflammation or the other measured serum markers. Interestingly, the effect of
intervention on phIGFBP-1, IGFBP-1 and MMP-8 showed an interaction with the maternal
BMI and on whether the mother would develop GDM. As GDM is detrimental to the
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health of the mother and child, means for early identification of women at risk of GDM,
such as measuring serum levels of phIGFBP-1 and IGFBP-1, could be useful for reducing
the possible health risks due to this disorder.
In contrast to our hypothesis and previous positive findings for the immunomodula-
tory effects of fish oil [38–41] and probiotics [29,30,42] which have been studied separately
in non-pregnant and pregnant adults, the dietary intervention did not influence the level
of low-grade inflammation or phIGFBP-1, IGFBP-1 or MMP-8 in the overweight and
obese pregnant women in this unique setting of studying either separately or a combi-
nation of both fish oil and probiotics. However, the impact of the intervention on these
metabolic markers analyzed was influenced by BMI and GDM, i.e., when compared to
overweight women, serum MMP-8 decreased more in obese women belonging to the
probiotics + placebo and fish oil + probiotics groups and IGFBP-1 increased more in obese
women in the fish oil + probiotics groups. In women with GDM, late pregnancy serum
levels of phIGFBP-1 were higher in the fish oil + probiotics group when compared to the
fish oil + placebo group. It seems that the combination of fish oil and probiotics may be
more effective in the regulation of IGFBP and MMP systems as compared to either fish
oil or probiotics alone if one takes into account the BMI and GDM status of the women.
Additionally, this could support the concept that these food supplements may be much
more efficacious in diseased populations (in this case, an obese population) rather than in
healthy, non-obese populations, where there may be nothing to improve. The results may
be interpreted so that fish oil and probiotic co-supplementation may have an beneficial
effect on IGFBP and MMP metabolism in pregnant women with high BMI or dysregulated
glucose metabolism; there is a need for further studies to verify the effects of a combination
of fish oil and probiotic supplementation.
In contrast to our results, fish oil has been shown to reduce hsCRP in a small group
of pregnant women (n = 25) consuming a similar dose of EPA and DHA, about 2 g per
day, from week 10 to 16 to term [15]. Furthermore, in two studies conducted in Iranian
women with GDM, a low dose of n-3 LC-PUFA (180 mg EPA and 120 mg DHA per day)
reduced the serum hsCRP level [13,43]. Previous studies with probiotics, which were
mainly conducted in Asian populations, while ours investigated a European population,
resulted in a significant decrease in the hsCRP level after consumption of Lactobacillaceae
and Bifidobacteriaceae [11,44,45], which may be due to the different dietary behavior but
also genetic background. In an overweight and obese adult population, the supplemen-
tation of Bifidobacterium animalis ssp. lactis 420 was shown to induce a tendency towards
a reduction in hsCRP [46]. Although our study was initiated in early pregnancy and
involved a larger population than those previous reports, we did not detect any statistically
significant effect; thus, it is noteworthy that the timing and duration of the intervention
and also probiotic strains or their combination may have an effect on the outcome, as well
as the study population in whom the intervention is conducted. Interestingly, in a recent
meta-analysis of randomized clinical trials, serum hsCRP decreased significantly in healthy
adults as well as in adults with a wide range of health conditions, except for patients
with metabolic diseases and those with allergy and autoimmune diseases, after probiotic
supplementation as compared to placebo [47].
In our study, serum hsCRP measured in early pregnancy did not predict the onset
of GDM in later pregnancy, which is in line with the report of Naser et al. [48]. In con-
trast, in another previous study, hsCRP levels were shown to be higher in women who
subsequently develop GDM [49]. Insulin has been suggested to control the transcription of
acute-phase protein genes [50] and thus Chan et al. [17] suggested that decreased insulin
sensitivity could increase the expression of hsCRP, which is likely to be the case in women
with GDM. Instead, we detected a greater decrease in serum hsCRP during pregnancy in
those women who developed GDM as compared to those women who remained healthy,
suggesting that pregnancy-induced changes in hsCRP are more established in women
developing GDM. Moreover, it has been shown that in both obese pregnant women and
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those with GDM, the inflammatory profiles are altered, not necessarily only increased but
also decreased, as compared to healthy normal weight women during pregnancy [51].
In terms of GDM and IGFPB-1, our results are in line with those of Qui et al. [52],
who showed that IGFBP-1 levels correlated inversely with the risk of developing GDM.
In another study, the extent of phosphorylation of cord blood phIGFBP-1 was related
to the levels detected in GDM and non-GDM women: highly phosphorylated IGFBP-1
levels decreased in women with GDM, but not those of the lesser phosphorylated IGFBP-1
as compared to healthy women in late pregnancy [53]. In our study, the phosphory-
lated form of IGFBP-1 was lower in women with GDM as compared to their healthy
counterparts at late pregnancy and was a more effective predictor of GDM than the non-
phosphorylated form, supporting the previous findings of phIGFBP in GDM. Considering
the non-phosphorylated IGFBP-1, Liao and co-workers [54] found lower levels of IGFBP-1
concentrations at week 20 of gestation in women with GDM in comparison to controls.
However, in another study, there were higher levels of IGFBP-1 in women with GDM than
in their healthy counterparts, but this study was conducted at 24–28 weeks of gestation [55].
In diabetes, including GDM, increased insulin levels may potentially lead to decreased
levels of IGFBP-1. IGFBP-1 affects glucose homeostasis by regulating the glucose lowering
effect of IGF-1. In experimental studies, it has been shown that exogenous administration of
IGF-1 results in enhanced insulin sensitivity and glucose uptake [9]. IGF-1 shares structural
components and effects with insulin and the bioavailability of IGF-1 is regulated by insulin.
Additionally, the production of IGFBP-1 is regulated by insulin [2]. In our study, IGFBP-1
as well as phIGFBP-1 were lower in early pregnancy in the women who developed GDM
in later pregnancy as compared to women who did not. We suggest that the lower levels
of early pregnancy may be related to the development of GDM in later pregnancy, as we
showed that low levels in early pregnancy remained low in women who developed GDM
in later pregnancy. It is possible that the phosphorylated form is responsible for these
effects, since the extent of phosphorylation of IGFBP-1 has an impact on the affinity of
IGF-1 for IGFBP-1 [53], thus further regulating the bioavailability of IGF-1. The mechanism
by which MMP-8 is related to obesity and insulin resistance is not completely clarified.
In this regard, MMP-8 can proteolytically modify insulin-receptor leading potentially to
development of insulin resistance [10].
Mechanisms between IGFBP-1, phIGFBP-1, and MMP-8 and probiotics and/or fish oil
are not known in detail. Probiotics may affect the protein synthesis of IGFBPs [22], while n-
3 LC-PUFA stimulate MMP production via prostaglandin production [56]. Other possible
mechanisms may relate to the short chain fatty acid production of probiotics and anti-
inflammatory properties of fish oil as suggested by Yan et al. [57] and by Gholamhosseini
et al. [20], respectively. To our knowledge, not much is known about the dietary regulators
of IGFBP-1 and MMP-8. One study showed that carbohydrates, plant protein and milk
protein were directly associated with IGFBP-1 [58], and protein restriction has been shown
to decrease the levels of IGFBP-1 [59]. Regarding MMP-8, the studies investigating the
impact of diet on MMP-8 are lacking. Previously, we investigated phIGFBP-1, IGFBP-1 and
MMP-8 in smaller number of pregnant women (n = 100) and we found that polyunsaturated
fatty acids correlated directly with IGFBP-1 and potassium and pyridoxine inversely with
MMP-8 [7].
We showed that serum hsCRP and MMP-8 decreased while IGFBP-1 and phIGFBP-1
increased during pregnancy, regardless of the intervention or GDM status. Our findings
with respect to the changes of IGFBP-1 and hsCRP during pregnancy are in agreement
with the results of previous studies [60–63] but some discrepancies exist regarding hsCRP,
e.g., a study conducted in non-obese pregnant women with GDM detected an elevation in
hsCRP along with the gestational age [64]. The MMP-8 level declined, which is in contrast
to previous studies in which increased MMP-8 levels were related to adverse pregnancy
outcomes including preterm delivery [65] or high amniotic fluid MMP-8 in intra-amniotic
inflammation [5]. However, the levels of MMP-8 as well as those of phIGFBP-1 and IGFBP-1
correlated with hsCRP in our study, and previously the levels of IGF-1 and IGFBPs, such
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as IGFBP-4, have been shown to associate with those of CRP and IL-6 [66]. Thus, our
study and previous reports indicate that the IGF-system may be linked to low-grade
inflammation.
In terms of vaginal samples, we did not detect IGFBP but did find evidence of MMP-
8 in both the early and the late pregnancy samples. We did not find any difference
between the first and the second measurement of MMP-8 during pregnancy, nor did
Rahkonen et al. [67] although they detected an association between an increased MMP-
8 level and bacterial vaginosis and leukocytosis in the first and the second trimester
suggesting a link between MMP-8 and elevated levels of inflammation. We measured
low-grade inflammation as reflected by hsCRP but did not find any association between
vaginal MMP-8 and hsCRP levels. These results indicate that the inflammatory state during
gestation is not stable but instead tends to vary, depending on many factors, such as
BMI [60].
In our study, we did not find differences between the intervention groups in the
amount of bleeding (>1000 mL); this result was reported in Pellonperä et al. [26]. More-
over, other adverse effects were very minimal e.g., headache or gastrointestinal symptoms.
Thus, the intervention was safe and well tolerated. These findings are in line with pre-
vious reports [68] and European Food Safety Authority evaluation [69], i.e., it is safe to
consume fish oil during pregnancy. The strengths of our study lie in its unique four group
factorial design with two active dietary ingredients, fish oil and probiotics, and in a well-
characterized study population, as well as an evaluation of the markers in both the serum
and vagina. As far as we are aware, this is the first clinical trial investigating the synergistic
benefits of fish oil and probiotics in pregnant women. However, this is a secondary analysis
of the main trial. Yet, previous studies investigating the impact of the dietary intervention
on low-grade inflammation included lower number of patients (ranging from 40 to 72)
than ours and still found significant results [11,13–15,42–45]. Furthermore, unlike the
previous studies, we took into consideration the overweight and obesity status. We aimed
to study an overweight and obese group of pregnant women at risk for gestational diabetes
and it remains for further studies to demonstrate if similar findings are seen in normal
weight pregnant women, which is one limitation of our study. Other limitations could be
the small number of vaginal samples, the fact that secondary outcomes of the main trial
were investigated, and that we only studied hsCRP as a marker for inflammation. We could
not detect the levels of IGFBP-1 and phIGFBP-1 in the vaginal samples which could be due
to the sample number or very low levels in this group with a low prevalence of preterm
deliveries, but this finding needs to be confirmed.
5. Conclusions
The extent of low-grade inflammation, as determined by hsCRP, and the levels of
the metabolic markers, IGFBP-1, phIGFBP-1 and MMP-8, were altered during pregnancy,
indicating changes in inflammatory and metabolic status in overweight and obese women
throughout gestation. This change was not influenced by our fish oil and/or probiotic
intervention, but it was noted that there was an interaction between how the intervention
altered the metabolic markers depending on the women’s obesity status and whether or
not they developed GDM. Our observations call for further studies in order to clarify
the potential benefits of this kind of intervention in pregnant women, particularly those
at an increased risk for health complications. The serum concentrations of IGFBP-1 and
phIGFBP-1 were lower in early pregnancy in those women who subsequently developed
GDM in later pregnancy, suggesting their potential as early markers for GDM. The result
of our study together with previous reports indicate that IGFBPs may have a role in the
development of GDM via the regulation of the glucose and insulin metabolism. At the
same time, supplementing the diet of pregnant women with fish oil and/or probiotics
supplementation needs to be investigated further, since we showed that serum levels of
IGFBP and MMP vary depending not only on the BMI and GDM status but also on whether
the pregnant woman received a supplementation with fish oil and/or probiotics.
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